HU HUM Humana Inc. Loading... : Bullish and Bearish Analyst Opinions

Premarket movers include Avantor rising 4% on earnings beat.

Management reiterated confidence in achieving its 2028 margin target of at least 3%, with meaningful progress expected in 2027, driven by cost actions and bidding strategy. The tone is cautiously optimistic with a focus on execution.

US pre-market movers report shows mixed earnings reactions with Meta and Microsoft slightly.

Humana reports second quarter earnings in line with guidance and affirms full-year adjusted EPS.

Humana reports Q2 2026 revenue of 40.87 billion dollars and adjusted EPS of 7.61 dollars.

Humana reports Q2 2026 revenue of 40.87 billion dollars and adjusted EPS of 7.61 dollars.

The Trump administration plans to end a Medicare drug-plan subsidy program.

UHS saw a one-for-one shift from exchange volumes to self-pay volumes, indicating that most patients losing exchange coverage are becoming uninsured. — This suggests the effective subsidy cliff is creating pure self-pay churn rather than conversion to other commercial products, a worse outcome for insurers exposed to the exchange market.

Buy Medicare Advantage insurers on cost decline.

Premarket movers report shows mixed Mag 7 stocks, ATAI surging on Eli Lilly acquisition talks.

Premarket movers report shows ASML up 3% on raised forecast, BlackRock up 4% on record inflows.

Humana Medicare Advantage reimbursement tailwind

Humana reiterates its full-year adjusted earnings per share guidance of at least nine dollars.

Buy HUM as GLP-1-driven weight loss reduces surgical and care utilization.

SEC FOIA logs reveal ongoing investigations for listed companies.

Aetna's medical benefit ratio of 84.6% was better than expected due to favorable prior year development, but management chose not to bake any of the current-year core outperformance into the full-year outlook, maintaining a cautious stance on medical cost trends. — Suggests either a future earnings beat if cost trends stay favorable or a prudent conservatism; implies sector-wide medical cost pressure persists.

Management is confidently reiterating its commitment to reach at least 3% MA margin in 2028, emphasizing progress on cost transformation and operational efficiency. They indicate that benefit adjustments for 2027 are necessary to bridge the funding gap versus medical cost trend, framing this as a disciplined step towards the long-term target.

Traderstewie shares a list of upcoming earnings from Earnings Whispers for the week of April 27.

Medicare Advantage rates were finalized at +2.48%, crushing the initial +0.09% proposal that previously caused the stock to fall. Humana is highly concentrated in Medicare Advantage; a better-than-feared reimbursement rate disproportionately benefits their top and bottom lines. The positive rate shock fundamentally improves the setup for Humana, reversing previous bearish sentiment tied to the January proposal. Medical cost trends (rising 7-9%) could still outpace the 2.48% reimbursement increase if benefits aren't trimmed.

The speaker explicitly stated "Humana is benefiting" following the announcement of the improved Medicare Advantage rate hike. Humana, as a major player in Medicare Advantage, faced significant downside risk from a 0% rate increase. The final 2.48% hike alleviates that pressure and improves the earnings outlook. LONG as the company is named a direct beneficiary of the positive regulatory development, which supports its core business model. The company's heavy exposure to Medicare Advantage makes it vulnerable to any future regulatory attempts to curtail payment growth more severely.

"when we see evidence of fraud, we stop the payments... We know that the American people are being defrauded. Let's try to stop the payments..." A crackdown on fraud in Medicaid and other health programs directly targets improper payments. Managed care organizations (MCOs) that administer these programs stand to benefit from reduced fraudulent claims leakage, which should improve their medical cost ratios (MCR) and profitability. Stricter oversight could also reduce competition from fraudulent providers. LONG on major Medicaid-managed care organizations. The crackdown could initially increase administrative costs for MCOs; overzealous enforcement might delay legitimate payments.

Trump attacks the Affordable Care Act, stating he wants to "stop all payments to big insurance companies" and notes that "insurance companies own Democrats." He also touts "Most Favored Nation" clauses dropping drug prices by 80%. The removal of federal subsidies/payments is a direct hit to the revenue of managed care organizations (UnitedHealth, Humana). Simultaneously, aggressive price controls on drugs compress margins for the broader healthcare/pharma sector. SHORT Managed Care and Big Pharma. Congressional gridlock preventing the removal of subsidies.

The President intends to "codify his health care framework that seeks to shift federal subsidies from health care companies to U.S. consumers." Managed Care Organizations (MCOs) and insurers rely heavily on government subsidies (particularly in Medicare Advantage). Shifting these funds directly to consumers bypasses the insurers, threatening their margins and revenue models. SHORT. This represents a structural change to healthcare funding flows detrimental to intermediaries. The complexity of healthcare reform often leads to watered-down implementation.

"I want to stop all payments to big insurance companies and instead give that money directly to the people... stock prices soared... like nothing else." The administration views the "middleman" model of Managed Care Organizations (MCOs) as the primary driver of healthcare inflation. Shifting federal subsidies (ACA/Medicare) directly to patients bypasses the insurers, threatening their revenue streams and margin compression. SHORT. The political target on the back of the insurance sector is now explicit policy. The lobby for healthcare insurers is powerful; implementation of direct payments may face logistical gridlock.

Under the "No Surprises Act," insurers are losing over 80% of arbitration cases to providers regarding out-of-network bills. This creates a structural headwind for margins as insurers are forced to pay higher rates than anticipated. Additionally, the State of the Union address is expected to target insurer profitability and affordability, adding headline risk. WATCH / AVOID. Regulatory relief or changes to the arbitration process could alleviate cost pressures.

Guidance points to a significant decline in EPS for 2026, driven by the large STARS headwind and slightly negative individual MA margins, though management emphasizes a doubling of margins when normalizing for STARS and sees growth as accretive to the enterprise.

CVS expects 2026 MBR to increase approximately 850 basis points from Q1 to Q4, a steeper seasonal curve than 2025, indicating higher expectations for medical cost trends in the first half of the year. — This signals a potentially slower start to 2026 for CVS and could indicate broader managed care industry trends of elevated costs into the new year.

A major shift in the Medicare market is underway: beneficiaries are moving from Medicare Advantage plans to Medicare Supplement plans due to MA reimbursement cuts and provider network constraints, fueling Globe Life's 50% sales surge at United American in 2025. — This structural shift pressures MA carriers (UNH, HUM, CVS) on enrollment and margins, while benefiting Med Supp writers like Globe Life.

The expiration of enhanced premium tax credits is expected to be a $40M headwind in 2026, but the fear of a mass exodus of patients from commercial plans is not materializing. Open enrollment performed better than expected, with patients proving 'sophisticated' in their insurance choices. — Resilient enrollment on ACA exchanges reduces the risk of volume loss and patient churn to other payers, a positive read for large health insurers with broad ACA exposure.

The administration proposed a "0.09% next year" payment increase. Holz notes investors were "positioning long thinking this was going to be a turnaround year," but now we are entering a "pocket now for a year, maybe two, in which earnings don't expand or grow." The macro environment for government-sponsored healthcare has shifted from a growth story to a stagnation story. While the stocks have dropped 20%, the fundamental driver for stock price appreciation (earnings growth) has been removed for the medium term. Buying the dip is premature because the capital will be tied up in a sector with no catalyst for 12-24 months. Do not buy the dip yet. The thesis has shifted from "turnaround" to "stagnation." The final ruling in April could be revised upward significantly, causing a relief rally (short squeeze).